AAAAAA

   
Results: 1-12 |
Results: 12
Locally inducible CD66a (CEACAM1) as an amplifier of the human intestinal T cell response
Authors: Donda, A Mori, L Shamshiev, A Carena, I Mottet, C Heim, MH Beglinger, C Grunert, F Rochlitz, C Terracciano, L Jantscheff, P De Libero, G
Citation: A. Donda et al., Locally inducible CD66a (CEACAM1) as an amplifier of the human intestinal T cell response, EUR J IMMUN, 30(9), 2000, pp. 2593-2603
Phase I clinical trial with IL-2-transfected xenogeneic cells administeredin subcutaneous metastatic tumours: clinical and immunological findings
Authors: Tartour, E Mehtali, M Sastre-Garau, X Joyeux, I Mathiot, C Pleau, J Squiban, P Rochlitz, C Courtney, M Jantscheff, P Herrmann, R Pouillart, P Fridman, WH Dorval, T
Citation: E. Tartour et al., Phase I clinical trial with IL-2-transfected xenogeneic cells administeredin subcutaneous metastatic tumours: clinical and immunological findings, BR J CANC, 83(11), 2000, pp. 1454-1461
Cancer gene and immunotherapy: recent developments
Authors: Jantscheff, P Herrmann, R Rochlitz, C
Citation: P. Jantscheff et al., Cancer gene and immunotherapy: recent developments, MED ONCOL, 16(2), 1999, pp. 78-85
Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors
Authors: Rochlitz, C Jantscheff, P Bongartz, G Dietrich, PY Quiquerez, AL Schatz, C Mehtali, M Courtney, M Tartour, E Dorval, T Fridman, WH Herrmann, R
Citation: C. Rochlitz et al., Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors, CANC GENE T, 6(3), 1999, pp. 271-281
Synovial PMN show a coordinated up-regulation of CD66 molecules
Authors: Honig, M Peter, HH Jantscheff, P Grunert, F
Citation: M. Honig et al., Synovial PMN show a coordinated up-regulation of CD66 molecules, J LEUK BIOL, 66(3), 1999, pp. 429-436
CD66a
Authors: Skubitz, KM Kuroki, M Jantscheff, P Skubitz, APN Grunert, F
Citation: Km. Skubitz et al., CD66a, J BIOL REG, 13(4), 1999, pp. 240-241
CD66b
Authors: Skubitz, KM Kuroki, M Jantscheff, P Skubitz, APN Grunert, F
Citation: Km. Skubitz et al., CD66b, J BIOL REG, 13(4), 1999, pp. 242-243
CD66c
Authors: Skubitz, KM Kuroki, M Jantscheff, P Skubitz, APN Grunert, F
Citation: Km. Skubitz et al., CD66c, J BIOL REG, 13(4), 1999, pp. 244-245
CD66d
Authors: Skubitz, KM Kuroki, M Jantscheff, P Skubitz, APN Grunert, F
Citation: Km. Skubitz et al., CD66d, J BIOL REG, 13(4), 1999, pp. 246-247
CD66e
Authors: Skubitz, KM Kuroki, M Jantscheff, P Skubitz, APN Grunert, F
Citation: Km. Skubitz et al., CD66e, J BIOL REG, 13(4), 1999, pp. 248-249
CD66f
Authors: Skubitz, KM Kuroki, M Jantscheff, P Skubitz, APN Grunert, F
Citation: Km. Skubitz et al., CD66f, J BIOL REG, 13(4), 1999, pp. 250-251
Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors: mechanism(s) of elimination of the transgene-carrying cells
Authors: Jantscheff, P Herrmann, R Spagnoli, G Reuter, J Mehtali, M Courtney, M Rochlitz, C
Citation: P. Jantscheff et al., Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors: mechanism(s) of elimination of the transgene-carrying cells, CANCER IMMU, 48(6), 1999, pp. 321-330
Risultati: 1-12 |